SEHK:2096Pharmaceuticals
What Is Driving Simcere Pharmaceutical Group (SEHK:2096) Higher Today?
Simcere Pharmaceutical Group (SEHK:2096) has hit two major milestones within days. Chinese regulators approved its Culevibart Injection for RSV prevention in newborns and infants, and Roche licensed SIM0660 with material upfront, milestone and royalty economics.
These twin announcements have come as Simcere Pharmaceutical Group’s share price has climbed 14.59% over the past 90 days, even though the 1-year total shareholder return is down 15.46% and the 3-year total shareholder return is up...